Apoptosis

Apoptosis(凋亡)

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

研究方向

Apoptosis 相关产品(2721)

  • GC62444 structure
    GC62444SDZ 224-015
    CAS: 161511-45-1

    SDZ 224-015 是具有口服活性的、IL-1β 转化酶和 caspase-1 的抑制剂。SDZ 224-015 具有抗COVID-19的活性,靶向 Mpro (IC50 of 30 nM)。

  • GC62451 structure
    GC62451Benpyrine
    CAS: 2550398-89-3
    纯度: >99.50%

    Benpyrine 是一种高度特异性的具有口服活性的 TNF-α 抑制剂,KD 值为 82.1 μM。Benpyrine 与 TNF-α 紧密结合并阻断其与 TNFR1 的相互作用,IC50 值为 0.109 µM。Benpyrine 可用于 TNF-α 介导的炎症和自身免疫性疾病的研究。

  • GC62453 structure
    GC62453GZD856 formic
    CAS: 2804039-78-7
    纯度: >98.00%

    GZD856 formic 是一种有效的和具有口服活性的 PDGFRα/β 抑制剂,IC50 值分别为 68.6 和 136.6 nM。GZD856 formic 也是 Bcr-AblT315I 的抑制剂,对天然 Bcr-Abl 和 T315I 突变型的 IC50 值分别为 19.9 和 15.4 nM。GZD856 formic 具有抗肿瘤活性。

  • GC62455 structure
    GC62455RIPK3-IN-1
    CAS: 2361139-70-8
    纯度: >98.50%

    RIPK3-IN-1 是 II 型 RIPK3 DFG-out 位点抑制剂,IC50 为 9.1 nM。RIPK3-IN-1 抑制 RIPK1 和 RIPK2,IC50 为 5.5 和 >10 μM。RIPK3-IN-1 还是 c-Met 激酶抑制剂,IC50 为 1.1 μM。

  • GC62457 structure
    GC62457UZH1
    纯度: >99.50%

    UZH1 是 UZH1a 和 UZH1b 的外消旋体。UZH1a 是一种有效和选择性的 METTL3 抑制剂,IC50 值为 280 nM。UZH1b (IC50=28 µM) 基本无活性。UZH1 可用于细胞进程的转录组调控。UZH1 具有抗肿瘤活性。UZH1 也可用作研究 METTL3 的化学探针。

  • GC62478 structure
    GC62478ζ-Stat
    CAS: 3316-02-7
    纯度: >99.50%

    ζ-Stat (NSC37044) is a specific and atypical protein kinase Cζ (PKCζ) inhibitor, with an IC50 of 5 μM.

  • GC62483 structure
    GC62483Pomolic acid
    CAS: 13849-91-7
    纯度: >98.00%

    Pomolic acid is a pentacyclic triterpene isolated from Euscaphis japonica, and is highly effective in inhibiting cell growth and induces apoptosis.

  • GC62487 structure
    GC62487POMHEX
    CAS: 2004714-34-3
    纯度: >98.00%

    POMHEX 是一个消旋混合物,是具有细胞渗透性的 HEX 的 POM 前体药物,是ENO2 的特异性抑制剂。POMHEX 对ENO1 缺失的细胞表现出低纳摩尔级别活性,并对 ENO1 缺失的肿瘤模型表现出良好的抗癌效果。POMHEX 是有效的糖酵解抑制剂。

  • GC62499 structure
    GC62499ATH686
    CAS: 853299-52-2
    纯度: >99.50%

    ATH686 是一种有效的,选择性的,ATP 竞争性的 FLT3 抑制剂。ATH686 靶向突变 FLT3 蛋白激酶活性,并通过诱导凋亡 (apoptosis) 和抑制细胞周期来抑制具有 FLT3 突变的细胞的增殖。ATH686 具有抗白血病作用。

  • GC62502 structure
    GC62502PD-1/PD-L1-IN-NP19
    CAS: 2377916-66-8
    纯度: >98.00%

    A PD-1/PD-L1 interaction inhibitor

  • GC62505 structure
    GC62505Pelcitoclax
    CAS: 1619923-36-2

    Pelcitoclax (APG-1252) 是一种有效的 Bcl-2/Bcl-xl 抑制剂,具有抗肿瘤和促凋亡作用。

  • GC62528 structure
    GC62528(Rac)-Hesperetin
    CAS: 69097-99-0
    纯度: >97.00%

    (Rac)-Hesperetin 是Hesperetin 的外消旋体。 Hesperetin 是一种天然黄烷酮类物质,为有效的,广谱的人 UGT 抑制剂。Hesperetin 可通过激活 p38 MAPK 来诱导凋亡。

  • GC62536 structure
    GC62536Bromelain
    CAS: 9001-00-7

    A mixture of proteolytic enzymes

  • GC62554 structure
    GC62554S65487
    CAS: 1644600-79-2
    纯度: >99.00%

    S65487 (VOB560) 是一种有效的选择性 Bcl-2 抑制剂。 S65487 对 BCL-2 突变也有活性,例如 G101V 和 D103Y。S65487 对 MCL-1,BFL-1 和 BCL-XL 的亲和力较差。S65487 诱导细胞凋亡 (apoptosis) 并具有抗癌活性。

  • GC62557 structure
    GC62557MDM2-IN-1
    CAS: 1410737-09-5
    纯度: >95.00%

    MDM2-IN-1 (Compound 30) 是一种合成的 MDM2-p53 相互作用 (MDM2) 抑制剂,包含反式 (D-)构型。

  • GC62558 structure
    GC62558WDR5-IN-1
    CAS: 2408842-51-1
    纯度: >98.50%

    WDR5-IN-1 是一种有效的选择性 WD 重复结构域 5 (WDR5) 抑制剂,Kd 为 <0.02 nM。WDR5-IN-1 抑制 MLL1 组蛋白甲基转移酶活性 (HMT),IC50为 2.2 nM。WDR5-IN-1 减少 WDR5 移位基因的 MYC 募集,并在 CHP-134 (神经母细胞瘤) 和 Ramos (Burkitt淋巴瘤) 细胞系中显示出有效的抗增殖作用。

  • GC62561 structure
    GC62561CCT369260
    CAS: 2647503-57-7
    纯度: >99.00%

    CCT369260 (compound 1) 是具有口服活性的、B 细胞淋巴瘤 6 (BCL6) 抑制剂,具有抗肿瘤活性,其 IC50 值为 520 nM。

  • GC62562 structure
    GC62562EGFR-IN-11
    CAS: 2463200-44-2
    纯度: >99.50%

    EGFR-IN-11 是第四代 EGFR-酪氨酸激酶抑制剂 (EGFR-TKI),对三重突变的 EGFRL858R/T790M/C797S 的 IC50 为 18 nM。EGFR-IN-11 显著抑制 EGFR 磷酸化,诱导细胞凋亡,将细胞周期阻滞在 G0/G1处。

  • GC62567 structure
    GC62567Pralnacasan
    CAS: 192755-52-5

    Pralnacasan (VX-740) 是一种有效的,选择性的,非肽型,具有口服活性白介素 1β 转化酶 (ICE, caspase 1) 抑制剂,Ki 为 1.4 nM。Pralnacasan 抑制促炎细胞因子 IL-18,IL-1β 和 IFN-γ。Pralnacasan 有潜力用于骨关节炎和类风湿关节炎的研究。

  • GC62590 structure
    GC62590E64FC26
    CAS: 2285446-62-8
    纯度: >99.00%

    E64FC26 是蛋白质二硫键异构酶 (PDI) 家族的一种有效的泛抑制剂,对 PDIA1、PDIA3、PDIA4、TXNDC5 和 PDIA6 的 IC50 分别为 1.9、20.9、25.9、16.3 和 25.4 μM。E64FC26 显示抗骨髓瘤活性。

  • GC62594 structure
    GC62594hnRNPK-IN-1
    CAS: 2313528-04-8
    纯度: >97.00%

    hnRNPK-IN-1 是一种异质核糖核蛋白 K (hnRNPK) 结合配体,用 SPR 和 MST 测量的 Kd 值分别为 4.6 μM 和 2.6 μM。hnRNPK-IN-1 通过破坏 hnRNPK 和 c-myc 启动子的结合来抑制 c-myc 转录。hnRNPK-IN-1诱导 Hela 细胞凋亡 (apoptosis),并具有很强的抗肿瘤活性。

  • GC62596 structure
    GC62596CDK7-IN-3
    CAS: 2417302-07-7
    纯度: >99.50%

    CDK7-IN-3 (CDK7-IN-3) 是一种具有口服活性的高选择性非共价 CDK7 抑制剂,KD 为 0.065 nM。 CDK7-IN-3 对 CDK2 (Ki=2600 nM)、CDK9 (Ki=960 nM)、CDK12 (Ki=870 nM) 显示出较差的抑制作用。 CDK7-IN-3 诱导肿瘤细胞凋亡并具有抗肿瘤活性。

  • GC62598 structure
    GC62598MI-1061 TFA
    CAS: 1410737-35-7

    MI-1061 TFA 是一种有效的,口服可生物利用的,化学稳定性的 MDM2 (MDM2-p53 互作) 抑制剂 (IC50=4.4 nM; Ki=0.16 nM)。MI-1061 TFA 激活小鼠 SJSA-1 异种移植瘤组织中 p53 并诱导凋亡,具有抗肿瘤活性。

  • GC62599 structure
    GC62599BCL6-IN-4
    CAS: 2253879-65-9
    纯度: >98.00%

    BCL6-IN-4 是一种有效的 B 细胞淋巴瘤 6 (BCL6) 抑制剂,IC50IC50 为 97 nM。BCL6-IN-4 具有抗肿瘤活性。